# Capnia

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/capnia

- Industry: Medical Devices & Equipment
- Headquarters: Redwood City, US
- Website: www.capnia.com
- Total disclosed funding: $31M
- Latest round: Series C (Nov 30, 2008)
- Investors on record: 5

## About

Capnia Inc. develops innovative medical devices focused on neonatal care, particularly for monitoring hemolysis and neurotoxic risks in newborns, facilitating timely clinical interventions.Founded in 1999 in Redwood City, US, Capnia Inc. specializes in neonatal health technology. The company has undergone strategic pivots, merging with Essentialis, Inc. in December 2016 to enhance its product offerings. Michael Wong, the founder, has a history of entrepreneurship, contributing to Capnia's direction. The company raised USD 3.10 mn in its most recent funding round in November 2014, amounting to a total of USD 3.10 mn raised across 7 deals.Capnia Inc. offers the CoSense® ETCOc Monitor, a device that non-invasively assesses hemolysis and neurotoxic risks in newborns. This monitor conducts breath tests to measure end-tidal carbon monoxide (ETCOc) levels, which are critical for managing jaundice. The device serves healthcare providers in U.S. hospitals and clinics, improving clinical outcomes for at-risk newborns.In the most recent year, 2014, Capnia reported a revenue amount of USD 0, with an EBITDA of USD -5,131,213.Capnia Inc. is focusing on expanding its product line and market reach. Following a successful IPO in November 2014, the company plans to leverage its recent funding to enhance the CoSense® ETCOc Monitor and explore the launch of additional healthcare solutions in the neonatal sector. The company is targeting further expansion into international markets to increase the accessibility of its technology. The merger with Essentialis, Inc. aims to bolster its product offerings and market presence.

## Funding rounds

- Series C, Nov 30, 2008, $19M — Teknoinvest Management, Vivo Capital, Asset Management Ventures
- Series B, May 3, 2004, $12M — Teknoinvest Management, BioAsia Investments, Asset Management Ventures, Novel Bioventures

## Investors

- Teknoinvest Management (https://capitalatlas.ai/funds/teknoinvest-management) — Series B, Series C
- BioAsia Investments (https://capitalatlas.ai/funds/bioasia-investments) — Series B
- Asset Management Ventures (https://capitalatlas.ai/funds/asset-management-ventures) — Series B, Series C
- Novel Bioventures — Series B
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series C